A Novel Donor-Acceptor Fluorescent Sensor for Zn2+ with High Selectivity and its Application in Test Paper.

A novel donor-acceptor fluorescent sensor was designed and synthesized. The sensor exhibited high selectivity and sensitivity to Zn2+ in acetonitrile solution. When 3.0 equiv. of Zn2+ was added gradually, the emission intensity at 500 nm increased 54-fold, accompanied by the fluorescent color of the solution changed from dark to green. Job's plot and ESI-MS were carried out to verify a 1:1 stoichiometric complex was formed between the sensor and Zn2+. The limit of detection (LOD) to Zn2+ was measured to be 2.81 × 10-9 mol L-1. Moreover, the sensor not only could be used to detect Zn2+ in practical water samples with high accuracy, but also could be made into test paper for the qualitative detection for Zn2+.

Baicalin induced colon cancer cells apoptosis through miR-217/DKK1-mediated inhibition of Wnt signaling pathway.

To analyze the anti-tumor mechanism of Baicalin in human colon cancer. The MTT assay and colony formation assay demonstrated that Baicalin treatment inhibits the proliferation of DLD1 and HCT-116 cells. The apoptosis rates were induced upon Baicalin treatment and which was determined by FACS. The qPCR and western blot analysis showed that Baicalin promotes expression of DKK1 (Dickkopf), an important antagonist of Wnt signaling pathway, thereby reduces the expression of its downstream protein ß-catenin and c-Myc. Reduction of DKK1 expression by siRNA attenuates ß-catenin and c-Myc expression. microRNA-217 (miR-217) is decreased upon Baicalin treatment. Moreover, DKK1 is identified as the direct downstream target gene of miR-217 through the dual-luciferase reporter assay. miR-217/DKK1-mediated inhibition of Wnt signaling pathway participate in apoptosis induced by Baicalin.

Gut microbiota dysbiosis in male patients with chronic traumatic complete spinal cord injury.

BACKGROUND: Neurogenic bowel dysfunction (NBD) is a major physical and psychological problem in patients with spinal cord injury (SCI), and gut dysbiosis is commonly occurs in SCI. Here, we document neurogenic bowel management of male patients with chronic traumatic complete SCI in our centre and perform comparative analysis of the gut microbiota between our patients and healthy males. METHODS: A total of 43 male patients with chronic traumatic complete SCI (20 with quadriplegia and 23 with paraplegia) and 23 healthy male adults were enrolled. Clinical data and fresh stool specimens were collected from all participants. Face-to-face interviews were conducted to survey the neurogenic bowel management of 43 patients with SCI. Gut microbiomes were analysed by sequencing of the V3-V4 region of the 16S rRNA gene. RESULTS: NBD was common in adult male patients with chronic traumatic complete SCI. Patients with quadriplegia exhibited a longer time to defecate than did those with paraplegia and had higher NBD scores and heavier neurogenic bowel symptoms. The diversity of the gut microbiota in the SCI group was reduced, and the structural composition was different from that of the healthy adult male group. The abundance of Veillonellaceae and Prevotellaceae increased, while Bacteroidaceae and Bacteroides decreased in the SCI group. The abundance of Bacteroidaceae and Bacteroides in the quadriplegia group and Acidaminococcaceae, Blautia, Porphyromonadaceae, and Lachnoclostridium in the paraplegia group were significantly higher than those in the healthy male group. Serum biomarkers (GLU, HDL, CR, and CRP), NBD defecation time and COURSE had significant correlations with microbial community structure. Microbial community structure was significantly associated with serum biomarkers (GLU, HDL, CR, and CRP), NBD defecation time, and COURSE. CONCLUSIONS: This study presents a comprehensive landscape of the gut microbiota in adult male patients with chronic traumatic complete SCI and documents their neurogenic bowel management. Gut microbiota dysbiosis in SCI patients was correlated with serum biomarkers and NBD symptoms.

Dysbiosis of gut microbiota is associated with serum lipid profiles in male patients with chronic traumatic cervical spinal cord injury.

Neurogenic bowel dysfunction (NBD) and gut dysbiosis frequently occur in patients with traumatic cervical spinal cord injury (TCSCI). We evaluated neurogenic bowel management and changes in the gut microbiota in patients with TCSCI as well as associations between these changes and serum biomarkers. Fresh fecal and clinical data were collected from 20 male patients with TCSCI and 23 healthy males. Microbial diversity and composition were analyzed by sequencing the V3-V4 region of the 16S rRNA gene. Moderate NBD was observed in patients with TCSCI. The diversity of the gut microbiota was lower in patients with TCSCI than in healthy adults. Furthermore, patients with TCSCI showed altered levels of serum biomarkers related to lipid metabolism, indicating unfavorable lipid profiles. Interestingly, Firmicutes had a positive effect and Verrucomicrobia had a negative effect on lipid metabolism (P < 0.05). At the genus level, Bacteroides and Blautia were significantly more abundant in patients than in healthy subjects and could be associated with lipid metabolism (P < 0.05). Faecalibacterium, Megamonas, and Prevotella, which were correlated with lipid metabolism markers, may be suitable targets for the treatment of TCSCI. Lactobacillus was positively correlated with glucose levels. The dysbiosis of several key gut bacteria was associated with serum biomarkers of lipid metabolism in patients with TCSCI. The observed interdependency of the microbiota and lipid metabolism provides a basis for understanding the mechanisms underlying lipid disorders after cervical SCI.

Antidiabetic Activity of Picris japonica Thunb Aqueous Extract in Diabetic KK-Ay Mice.

OBJECTIVE: To evaluate the hypoglycemic effect of Picris japonica Thunb (Asteraceae) on KK-Ay mice. METHODS: The hypoglycemic effect of Picris japonica aqueous extract (PJE) in a spontaneous type 2 diabetic model (KK-Ay mice) was studied in the present research. PJE was administrated at doses of 700 mg/kg and 350 mg/kg (calculated as crude herb) for 14 days and blood glucose, oral glucose tolerance test, plasma insulin level, and blood lipid were evaluated. Meanwhile, Rosiglitazone was used for the positive control. RESULTS: It was found the PJE treatment significantly reduced blood glucose level and improved oral glucose tolerance ability (p < 0.01 or p < 0.05) in a dose-dependent manner compared to the control diabetic mice. The blood insulin levels were significantly reduced in PJE-treated mice (700 mg/kg) and Rosiglitazone compared with the diabetic control (p < 0.01). Compared with the control diabetic group, the serum total cholesterol, triglyceride, and low density lipoprotein cholesterol were reduced by PJE (700 mg/kg) and Rosiglitazone (p < 0.05), and the serum high density lipoprotein cholesterol was significantly increased only by Rosiglitazone (p < 0.01). CONCLUSIONS: The findings demonstrate that Picris japonica has remarkable antidiabetic effect in diabetic KK-Ay mice, which suggests that Picris japonica may be beneficial to the treatment of type 2 diabetes mellitus.